17MA030T2-Bispecific CAR-T Cell Constructs For Acute Myeloid Leukemia Treatment

CD33 or CD123 targeted Chimeric Antigen Receptor (CAR) T cell therapies have shown promise but struggle with on target off tumor toxicities, complicated allogeneic HSC transplants and AML relapse. In response, novel bispecific human CD33/123 CAR T cells with split signaling costimulation domains were highly efficacious in vitro at killing target cells, proliferating and generating substantial amount of cytokines.

Contact:
Haskell Adler, PhD, MBA, CLP
Haskell.Adler@Moffitt.org

свернуть